Head-to-head evidence
Olezarsen vs RN0361
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: APOC3 · full Atherosclerotic Cardiovascular Disease pipeline
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals
NCT05610280 · Phase 3 · completed
This was a large, randomized, placebo-controlled trial in which participants, care providers, investigators and outcome assessors were all kept blind to treatment assignment. Its primary endpoint, the reduction in fasting triglycerides, was clearly met, with both olezarsen doses producing a large, statistically significant drop versus placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05681351 (registry estimate)
RN0361
Developed by Rona Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olezarsen's landscape · RN0361's landscape